Barbados eyes billions from microbe patents as scientist rejects pharma buyout

UWI researcher’s discovery could reshape the island’s biotech future and revive its storied scientific legacy.

Barbados is positioning itself to capitalize on a significant biotechnology breakthrough after Dr Bidyut Mohapatra, a researcher at UWI Cave Hill, declined lucrative offers from three major pharmaceutical companies to sell his microbe discoveries. Instead, the scientist chose to work with the Barbados government to secure patents domestically, a decision that has drawn praise from the island’s export promotion leadership.

According to Barbados Today, Mark Hill, Chief Executive Officer of Export Barbados, described the move as a critical step toward building new industries around what he calls the “3Ms”—molecules, microbes, and materials. The government’s patent effort is being led by Minister of Industry, Innovation, Science and Technology Jonathan Reid, following discussions with Prime Minister Mia Mottley and Dr Mohapatra. Hill emphasized that securing intellectual property before entering licensing deals with pharmaceutical companies is essential to maintaining Barbados’ negotiating leverage and equity.

The microbes under patent protection are being explored for their potential to address three major global challenges: antimicrobial resistance, microplastic pollution, and ocean damage. Hill noted that antimicrobial resistance alone represents a billion-dollar opportunity within the global healthcare system, with the combined potential of these applications reaching into the billions. Export Barbados is supporting the effort through its “ID to IP” programme, which provides legal and structural assistance for obtaining international patents.

The initiative reflects a deliberate strategy to revive Barbados’ historical standing as a center of scientific excellence. The island has deep roots in agricultural innovation, including pioneering work in sugarcane genetics dating to the 1880s, when agronomist John Redman Bovell developed new cane varieties that established Barbados as a leading breeding center in the Caribbean. Hill framed the current microbe patents as a natural extension of this legacy, positioning advanced biological research as consistent with the island’s established strengths in the life sciences.

Beyond immediate financial returns, Hill suggested that commercial royalties, licensing fees, and reinvestment could energize Barbados’ scientific community and demonstrate that a small island can compete at the highest levels of biotechnology research. The strategy underscores a broader government focus on re-industrializing the island around science and technology rather than traditional sectors.

Barbados has a documented history of scientific achievement in agriculture and fermentation. In the 1880s, agronomist John Redman Bovell conducted his own breeding experiments with sugarcane varieties, moving away from the widely used Bourbon cane to focus on the White Transparent variety. His work helped establish Barbados as one of the Caribbean’s leading cane-breeding centers. Bovell also developed several strains of Sea Island cotton, and his contributions were honored when his portrait was used on the Barbados $2 bill introduced in 1980, 52 years after his death.

This development signals a potential shift in how Caribbean nations approach intellectual property and scientific innovation. Barbados’ decision to retain ownership of biotech discoveries rather than sell to foreign corporations could serve as a model for other Caribbean islands seeking to build knowledge-based economies and retain equity in their scientific breakthroughs. The emphasis on leveraging historical scientific strengths also reflects broader Caribbean efforts to diversify economies beyond tourism and traditional agriculture.

Written & Edited by Orlyn Edwards. Published by Caribbean Air Force Media.

Category: Business · Island routing: Barbados